Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Sinopharm was founded as China National Pharmaceutical Group Corporation on November 26, 1998, as a holding company for China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation , China National Pharmaceutical Foreign Trade Corp. and China National Medical Device . In 2009 it was merged with China National Biotec Group .Its subsidiary Wuhan Institute of Biological Products was fined for selling 400,520 ineffective DPT vaccines in November 2017.
Ms. Xiaojuan Li (Chief Financial Officer)
Mr. Yijian Wu (Sec. to the Board, Company Sec. & Authorised Representative)
Mr. Wanyong Lian (VP)
Mr. Shuangjun Xu (Non-Exec. VP)
Mr. Maisong Cai (VP)
Sinopharm Group Co., Ltd. has won numerous awards for its products and services, such as the Golden Globe Award for Most Influential Pharmaceutical Company in China in 2013 and The Pharma Times Award for Drug Manufacturer of the Year in 2015.
China 
